Multiple cancer vaccine platforms have been developed, including cell-based, peptide- or protein-based, viral-based, and nucleic acid-based vaccines to elicit CD8+ cytotoxic T lymphocyte (CTL), a pivotal effector cell in tumor immunity. The gene discussed is CD8A; the disease is neoplasm.